|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for MEF2C(NM_002397.4) Search again
Product ID:
HQP011151
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
C5DELq14.3, DEL5q14.3, NEDHSIL
Gene Description:
myocyte enhancer factor 2C
Target Gene Accession:
NM_002397.4(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Gene References into function
- MEF2C carboxy terminus (aa 387-473) deletion enhances transcriptional activation. AA 312-367 coupled with aa 1-86 activates transcription. Deletion of aa 312-350 decreases transcription.
- The C-terminal region in MEF2C contains signals that are necessary to localize the histone deacetylase 4/MEF2 complex to the nucleus.
- The DNA-binding TEA domain of transcription factor TEF-1 interacts with the MADS/MEF2 domain of MEF2C.
- upregulation of expression by C-terminus of myogenin
- The skeletal muscle-specific transcription cofactor vestigial-like 2 interacts with the C-terminal domain of MEF2C.
- myogenin and myocyte enhancer factor-2 expression are triggered by membrane hyperpolarization during human myoblast differentiation
- MEF2C is acetylated by p300 both in vitro and in vivo, which enhances its DNA binding activity, transcriptional activity, and myogenic differentiation.
- A conserved pattern of alternative splicing in vertebrate MEF2 (myocyte enhancer factor 2) genes generates an acidic activation domain in MEF2 proteins selectively in tissues where MEF2 target genes are highly expressed. (MEF2)
- data show a dosage-dependent cardiomyopathic phenotype and a progressive reduction in ventricular performance associated with MEF2A or MEF2C overexpression
- Phosphorylation of MEF2C at S396 aids sumoylation at K391, which recruits yet unidentified corepressors to inhibit transcription. Sumoylation motifs with a phosphorylated serine or an acidic residue at the +5 position might be more efficiently sumoylated
- Study demonstrates that human intestinal cell BCMO1 expression is dependent on the functional cooperation between peroxisome proliferator-activated receptor-gamma and myocyte enhancer factor 2 isoforms.
- Overexpression of MEF2C is associated with hepatocellular carcinoma
- Results show the altered interaction between the different variants in the PGC-1alpha gene and MEF2C may attribute to the susceptibility to type 2 diabetes in the southern Chinese population.
- In T-ALL cell lines, MEF2C is activated by NKX2-5 at both the RNA and protein levels. MEF2C consistently inhibits expression of NR4A1/NUR77, which regulates apoptosis via BCL2 transformation.
- the association of the 482G/A polymorphism of the PGC-1alpha gene with type 2 diabetes and the quantitative and qualitative binding force changes between the PGC-1alpha domain mutant and MEF2C